Trialtrove’s annual review of clinical trials initiated by industry sponsors is a useful gauge of the diversity and innovative potential of biopharma’s investments in R&D. This year’s report reveals that, while there are patterns of consistency in many aspects of the trial landscape, changes are in the wind – particularly as companies outside the pharma top 20 now contribute more completed trials than any other type of sponsor.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2019.

Gilead signed two big oncology deals with Nurix and Carna. AbbVie bought Botox maker Allergan for $63 billion. FOPOs led biopharma financing, while debt represented the most dollars in device fundraising.

What is a medicines shortage? The answer may seem obvious, but the fact that European regulators have only now come up with a commonly agreed definition suggests otherwise.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June 2019.

As it plans to focus on core therapy areas following the Shire acquisition, Takeda divested dry eye drug Xiidra to Novartis for up to $5.3bn. 3M bought wound care firm Acelity  from an investor consortium led by Apax partners for $6.7bn. Both pharma and device financing was up over the previous month, with strong showings from debt offerings.